Prokidney appoints bruce culleton, md, as executive vice president, clinical development and commercialization

- brings more than 20 years of academic and industry experience with extensive  expertise in kidney disease - winston-salem, n.c., july 17, 2023 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today announced the appointment of bruce culleton, md, as executive vice president, clinical development and commercialization.
PROK Ratings Summary
PROK Quant Ranking